Biotechnology · San Diego, California, United States
$15.64
-0.32% (-$0.05)2026-07-09
Smart-Money SignalNeutral · 49/100— Insiders are net sellers over 90 days (-$982K, 15 sales vs 7 buys)
Net Income-$14.5M
EPS$-0.39
Market Cap$361.3M
Price Performance
Historical data including institutional events
Company Profile
C
Carmine Stengone
CEO & Executive Director
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States.
The companyâs lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis.
The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023.
Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
